693 related articles for article (PubMed ID: 17897075)
1. Bioactivity of new mu and delta opioid peptides.
Capasso A
Med Chem; 2007 Sep; 3(5):480-7. PubMed ID: 17897075
[TBL] [Abstract][Full Text] [Related]
2. Opioid receptor selectivity alteration by single residue replacement: synthesis and activity profile of [Dmt1]deltorphin B.
Guerrini R; Capasso A; Sorrentino L; Anacardio R; Bryant SD; Lazarus LH; Attila M; Salvadori S
Eur J Pharmacol; 1996 Apr; 302(1-3):37-42. PubMed ID: 8790989
[TBL] [Abstract][Full Text] [Related]
3. Dmt-Tic-OH a highly selective and potent delta-opioid dipeptide receptor antagonist after systemic administration in the mouse.
Capasso A; Guerrini R; Balboni G; Sorrentino L; Temussi P; Lazarus LH; Bryant SD; Salvadori S
Life Sci; 1996; 59(8):PL93-8. PubMed ID: 8761022
[TBL] [Abstract][Full Text] [Related]
4. Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides.
Salvadori S; Attila M; Balboni G; Bianchi C; Bryant SD; Crescenzi O; Guerrini R; Picone D; Tancredi T; Temussi PA
Mol Med; 1995 Sep; 1(6):678-89. PubMed ID: 8529134
[TBL] [Abstract][Full Text] [Related]
5. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
[TBL] [Abstract][Full Text] [Related]
6. Interaction between the mu-agonist dermorphin and the delta-agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and delta-opioid receptor binding.
Negri L; Improta G; Lattanzi R; Potenza RL; Luchetti F; Melchiorri P
Br J Pharmacol; 1995 Dec; 116(7):2931-8. PubMed ID: 8680727
[TBL] [Abstract][Full Text] [Related]
7. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice.
Bilsky EJ; Inturrisi CE; Sadée W; Hruby VJ; Porreca F
Pain; 1996 Dec; 68(2-3):229-37. PubMed ID: 9121809
[TBL] [Abstract][Full Text] [Related]
8. Comparison with naloxone of two dynorphin A analogues with K- and delta-opioid antagonist activity.
Capasso A
Med Chem; 2009 Jan; 5(1):1-6. PubMed ID: 19149644
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties.
Balboni G; Guerrini R; Salvadori S; Bianchi C; Rizzi D; Bryant SD; Lazarus LH
J Med Chem; 2002 Jan; 45(3):713-20. PubMed ID: 11806723
[TBL] [Abstract][Full Text] [Related]
10. Conformationally restricted deltorphin analogues.
Schiller PW; Weltrowska G; Nguyen TM; Wilkes BC; Chung NN; Lemieux C
J Med Chem; 1992 Oct; 35(21):3956-61. PubMed ID: 1331451
[TBL] [Abstract][Full Text] [Related]
11. Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists.
Schiller PW; Nguyen TM; Weltrowska G; Wilkes BC; Marsden BJ; Lemieux C; Chung NN
Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11871-5. PubMed ID: 1334552
[TBL] [Abstract][Full Text] [Related]
12. (2S,3R) beta-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective delta-opioid receptor antagonist in mouse brain.
Hosohata K; Varga EV; Alfaro-Lopez J; Tang X; Vanderah TW; Porreca F; Hruby VJ; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 2003 Feb; 304(2):683-8. PubMed ID: 12538822
[TBL] [Abstract][Full Text] [Related]
13. Antinociceptive and behavioral effects of synthetic deltorphin analogs.
Negri L; Noviello L; Noviello V
Eur J Pharmacol; 1996 Jan; 296(1):9-16. PubMed ID: 8720471
[TBL] [Abstract][Full Text] [Related]
14. Design of mu selective opioid dipeptide antagonists.
Capasso A; Amodeo P; Balboni G; Guerrini R; Lazarus LH; Temussi PA; Salvadori S
FEBS Lett; 1997 Nov; 417(1):141-4. PubMed ID: 9395092
[TBL] [Abstract][Full Text] [Related]
15. N-terminal guanidinylation of TIPP (Tyr-Tic-Phe-Phe) peptides results in major changes of the opioid activity profile.
Weltrowska G; Nguyen TM; Chung NN; Wilkes BC; Schiller PW
Bioorg Med Chem Lett; 2013 Sep; 23(18):5082-5. PubMed ID: 23932788
[TBL] [Abstract][Full Text] [Related]
16. Conversion of delta-, kappa- and mu-receptor selective opioid peptide agonists into delta-, kappa- and mu-selective antagonists.
Schiller PW; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Lu Y
Life Sci; 2003 Jun; 73(6):691-8. PubMed ID: 12801590
[TBL] [Abstract][Full Text] [Related]
17. Effect of aromatic amino acid substitutions in the 3-position of cyclic beta-casomorphin analogues on mu-opioid agonist/delta-opioid antagonist properties.
Schmidt R; Wilkes BC; Chung NN; Lemieux C; Schiller PW
Int J Pept Protein Res; 1996 Nov; 48(5):411-9. PubMed ID: 8956074
[TBL] [Abstract][Full Text] [Related]
18. [Dmt(1)]DALDA is highly selective and potent at mu opioid receptors, but is not cross-tolerant with systemic morphine.
Riba P; Ben Y; Nguyen TM; Furst S; Schiller PW; Lee NM
Curr Med Chem; 2002 Jan; 9(1):31-9. PubMed ID: 11860345
[TBL] [Abstract][Full Text] [Related]
19. Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism.
Salvadori S; Guerrini R; Balboni G; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
J Med Chem; 1999 Dec; 42(24):5010-9. PubMed ID: 10585210
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of intrathecally administered delta and mu opioid receptor agonists on formalin-evoked nociception and on the expression of Fos-like immunoreactivity in the spinal cord of the rat.
Hammond DL; Wang H; Nakashima N; Basbaum AI
J Pharmacol Exp Ther; 1998 Jan; 284(1):378-87. PubMed ID: 9435201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
